Alen suffered from debilitating pain due to a chronic neurological condition. He had no choice but to take opioids to manage the pain but experienced unpleasant side effects, including fatigue, as a result.
Dr. Tatevossian recommended HF10 to 44-year-old Alen, who agreed to an HF10 trial in October 2017, followed by a November 2017 HF10 implant to control his leg pain. Less than a year later, in July 2018, Alen agreed to another HF10 trial to address upper extremity neuropathic pain and proceeded with his implant less than two months later.
“It is gratifying to see the remarkable improvement in Alen’s quality of life,” said Dr. Tatevossian. “Not only is Alen able to enjoy a more active lifestyle and time with his family but he has also been able to decrease his opioid intake by 75%.”
Results may vary. Important safety & risk information:http://ow.ly/2fUN50gfJxE